Incidence of Colorectal Cancer After Intestinal Infection Due to Clostridioides difficile.

IF 2.1 Q3 ONCOLOGY
World Journal of Oncology Pub Date : 2024-04-01 Epub Date: 2024-03-21 DOI:10.14740/wjon1802
Raina K Patel, Matthew Cardeiro, Lexi Frankel, Enoch Kim, Kazuaki Takabe, Omar M Rashid
{"title":"Incidence of Colorectal Cancer After Intestinal Infection Due to <i>Clostridioides difficile</i>.","authors":"Raina K Patel, Matthew Cardeiro, Lexi Frankel, Enoch Kim, Kazuaki Takabe, Omar M Rashid","doi":"10.14740/wjon1802","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Clostridioides difficile</i> (<i>C. difficile</i> or <i>C. diff</i>) is a toxin-producing bacteria that is notorious for causing life-threatening diarrhea. Recent literature has investigated various effects of <i>Clostridioides difficile</i> infection (CDI) in cancer patients, but research into the impact of CDI on the development of cancer and its effects on the microbiome is limited. CDI predominately affects the colon, which urges consideration into the sequalae of infection. This study investigated the correlation between CDI and the incidence of colorectal carcinoma (CRC).</p><p><strong>Methods: </strong>A retrospective study (2010 - 2020) was conducted using a Health Insurance Portability and Accountability Act (HIPAA) compliant national database. The International Classification of Disease ninth and 10th Codes (ICD-9, ICD-10), Current Procedural Terminology (CPT), and National Drug Codes were used to identify CRC diagnosis, CDI, and matching or control parameters. Patients were matched for age, sex, Charlson Comorbidity Index (CCI), region of residence, and CDI treatment. An additional, but separate, query was executed to include obese patients with and without CDI, who were similarly matched and assessed for CRC. Statistical analyses were implemented to assess significance and estimate odds ratios (ORs).</p><p><strong>Results: </strong>CDI was associated with a decreased incidence of CRC (OR = 0.59, 95% confidence interval (CI): 0.55 - 0.63), and the difference was statistically significant (P < 2.2 × 10<sup>-16</sup>). CDI treatment, including appropriate antibiotics and fecal microbiota transplant (FMT), was controlled for in both infected and noninfected populations. Patients with a prior CDI who received relevant treatment were compared to patients with no history of CDI and received analogous treatment. Both populations subsequently developed CRC. Results remained statistically significant (P < 2.2 × 10<sup>-16</sup>) with a relative risk (RR) of 0.57 (95% CI: 0.54 - 0.60). Obesity was explored as a controlled variable in relation to CRC development in patients with and without prior CDI. Obese patients without a history of CDI were found to have a decreased risk of developing CRC. Results were statistically significant (P < 4.3 × 10<sup>-13</sup>) with an OR of 0.70 (95% CI: 0.63 - 0.77).</p><p><strong>Conclusions: </strong>This study shows a statistically significant correlation between CDI and decreased incidence of CRC. Additionally, there is a statistically significant correlation between obese patients with CDI and an increased incidence of CRC. Further research is needed to explore the mechanism of this striking relationship and the implications of CDIs on the microbiome.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10965253/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon1802","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Clostridioides difficile (C. difficile or C. diff) is a toxin-producing bacteria that is notorious for causing life-threatening diarrhea. Recent literature has investigated various effects of Clostridioides difficile infection (CDI) in cancer patients, but research into the impact of CDI on the development of cancer and its effects on the microbiome is limited. CDI predominately affects the colon, which urges consideration into the sequalae of infection. This study investigated the correlation between CDI and the incidence of colorectal carcinoma (CRC).

Methods: A retrospective study (2010 - 2020) was conducted using a Health Insurance Portability and Accountability Act (HIPAA) compliant national database. The International Classification of Disease ninth and 10th Codes (ICD-9, ICD-10), Current Procedural Terminology (CPT), and National Drug Codes were used to identify CRC diagnosis, CDI, and matching or control parameters. Patients were matched for age, sex, Charlson Comorbidity Index (CCI), region of residence, and CDI treatment. An additional, but separate, query was executed to include obese patients with and without CDI, who were similarly matched and assessed for CRC. Statistical analyses were implemented to assess significance and estimate odds ratios (ORs).

Results: CDI was associated with a decreased incidence of CRC (OR = 0.59, 95% confidence interval (CI): 0.55 - 0.63), and the difference was statistically significant (P < 2.2 × 10-16). CDI treatment, including appropriate antibiotics and fecal microbiota transplant (FMT), was controlled for in both infected and noninfected populations. Patients with a prior CDI who received relevant treatment were compared to patients with no history of CDI and received analogous treatment. Both populations subsequently developed CRC. Results remained statistically significant (P < 2.2 × 10-16) with a relative risk (RR) of 0.57 (95% CI: 0.54 - 0.60). Obesity was explored as a controlled variable in relation to CRC development in patients with and without prior CDI. Obese patients without a history of CDI were found to have a decreased risk of developing CRC. Results were statistically significant (P < 4.3 × 10-13) with an OR of 0.70 (95% CI: 0.63 - 0.77).

Conclusions: This study shows a statistically significant correlation between CDI and decreased incidence of CRC. Additionally, there is a statistically significant correlation between obese patients with CDI and an increased incidence of CRC. Further research is needed to explore the mechanism of this striking relationship and the implications of CDIs on the microbiome.

艰难梭菌肠道感染后的大肠癌发病率。
背景:艰难梭状芽孢杆菌(C. difficile 或 C. diff)是一种产毒细菌,因导致危及生命的腹泻而臭名昭著。最近有文献调查了艰难梭菌感染(CDI)对癌症患者的各种影响,但关于艰难梭菌感染对癌症发展的影响及其对微生物组的影响的研究还很有限。CDI 主要影响结肠,因此需要考虑感染的后遗症。本研究调查了 CDI 与结直肠癌(CRC)发病率之间的相关性:这项回顾性研究(2010-2020 年)使用了符合《健康保险可携性与责任法案》(HIPAA)的国家数据库。国际疾病分类》第九和第十版代码(ICD-9、ICD-10)、《现行医疗程序术语》(CPT)和《国家药物代码》被用来确定 CRC 诊断、CDI 以及匹配或对照参数。患者的年龄、性别、Charlson 生病指数 (CCI)、居住地区和 CDI 治疗情况都是匹配的。另外,还执行了一项单独的查询,以纳入患有和未患有 CDI 的肥胖患者,这些患者也进行了类似的匹配和 CRC 评估。研究人员进行了统计分析,以评估显著性并估算出几率比(ORs):结果:CDI 与 CRC 发病率的降低有关(OR = 0.59,95% 置信区间 (CI):0.55 - 0.63),差异具有统计学意义(P < 2.2 × 10-16)。在感染和非感染人群中,CDI 治疗(包括适当的抗生素和粪便微生物群移植 (FMT))都得到了控制。曾患 CDI 并接受过相关治疗的患者与无 CDI 病史并接受过类似治疗的患者进行了比较。这两类人群随后都患上了 CRC。结果仍具有统计学意义(P < 2.2 × 10-16),相对风险 (RR) 为 0.57(95% CI:0.54 - 0.60)。研究人员将肥胖作为一个控制变量,探讨了曾患或未患过 CDI 的患者患上 CRC 的可能性。结果发现,无 CDI 病史的肥胖患者罹患 CRC 的风险较低。结果具有统计学意义(P < 4.3 × 10-13),OR 值为 0.70(95% CI:0.63 - 0.77):本研究表明,CDI 与 CRC 发病率下降之间存在统计学意义上的显著相关性。此外,患有 CDI 的肥胖患者与 CRC 发病率增加之间也存在统计学意义上的显著相关性。需要进一步研究探讨这种惊人关系的机制以及 CDI 对微生物组的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信